{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:00:06Z","timestamp":1774526406822,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Anhui Province Natural Science Research Project of Higher Education Institutions","award":["2023AH053174"],"award-info":[{"award-number":["2023AH053174"]}]},{"name":"Anhui Province clinical medical research transformation project","award":["202304295107020022"],"award-info":[{"award-number":["202304295107020022"]}]},{"name":"the Anhui Province Natural Science Foundation","award":["2208085MH194"],"award-info":[{"award-number":["2208085MH194"]}]},{"name":"Key Projects for the Collaborative Tackling of Major and Difficult Diseases with Integrated Traditional Chinese and Western Medicine","award":["2021zdynjb07"],"award-info":[{"award-number":["2021zdynjb07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15738-4","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T10:14:28Z","timestamp":1771496068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-related efficacy in non-small cell lung cancer: real-world incidence and management practices of 208 patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Yufang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changxiu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dahai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"3","key":"15738_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"15738_CR2","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"24","key":"15738_CR3","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"22","key":"15738_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"15738_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"7800","key":"15738_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-020-2124-0","volume":"579","author":"N Kanarek","year":"2020","unstructured":"Kanarek N, Petrova B, Sabatini DM. Dietary modifications for enhanced cancer therapy. Nature. 2020;579(7800):507\u201317.","journal-title":"Nature"},{"issue":"3","key":"15738_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","volume":"15","author":"NE Ready","year":"2020","unstructured":"Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and Nivolumab plus Ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020;15(3):426\u201335.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"15738_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/annonc\/mdz109","volume":"30","author":"S Peters","year":"2019","unstructured":"Peters S, Reck M, Smit EF, Mok T, Hellmann MD. How to make the best use of immunotherapy as first-line treatment of advanced\/metastatic non-small-cell lung cancer. Ann Oncol. 2019;30(6):884\u201396.","journal-title":"Ann Oncol"},{"issue":"11","key":"15738_CR9","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G Jr. de Castro","year":"2023","unstructured":"de Castro G Jr., Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, Caglevic C, Zhang L, Karaszewska B, Laktionov KK, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41(11):1986\u201391.","journal-title":"J Clin Oncol"},{"issue":"21","key":"15738_CR10","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.20.03579","volume":"39","author":"M Boyer","year":"2021","unstructured":"Boyer M, Sendur MAN, Rodriguez-Abreu D, Park K, Lee DH, Cicin I, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50%: randomized, double-blind phase III KEYNOTE-598 study. J Clin Oncol. 2021;39(21):2327\u201338.","journal-title":"J Clin Oncol"},{"issue":"16","key":"15738_CR11","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1158\/1078-0432.CCR-20-0175","volume":"26","author":"J Zugazagoitia","year":"2020","unstructured":"Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst RS, et al. Biomarkers associated with beneficial PD-1 checkpoint blockade in Non-Small Cell Lung Cancer (NSCLC) identified using high-plex digital spatial profiling. Clin Cancer Res. 2020;26(16):4360\u20138.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"15738_CR12","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Domine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15738_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723\u201333.","journal-title":"J Clin Oncol"},{"issue":"6","key":"15738_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol"},{"issue":"3","key":"15738_CR15","doi-asserted-by":"publisher","first-page":"e096617","DOI":"10.1136\/bmjopen-2024-096617","volume":"15","author":"RM Roesch","year":"2025","unstructured":"Roesch RM, Schnorbach J, Klotz LV, Griffo R, Thomas M, Stenzinger A, et al. NeoTRACK trial: neoadjuvant TiRagolumab, Atezolizumab and chemotherapy - dissection of IO- efficacy in NSCLC by longitudinal tracking - protocol of a non-randomised, open-label, single-arm, phase II study. BMJ Open. 2025;15(3):e096617.","journal-title":"BMJ Open"},{"issue":"1","key":"15738_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41392-024-01992-0","volume":"9","author":"H Duan","year":"2024","unstructured":"Duan H, Shao C, Luo Z, Wang T, Tong L, Liu H, et al. Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial). Signal Transduct Target Ther. 2024;9(1):296.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"15738_CR17","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, et al. The next decade of immune checkpoint therapy. Cancer Discov. 2021;11(4):838\u201357.","journal-title":"Cancer Discov"},{"issue":"21","key":"15738_CR18","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"15738_CR19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, Gumus M, Vicente D, Mazieres J, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncol"},{"key":"15738_CR20","doi-asserted-by":"publisher","first-page":"703143","DOI":"10.3389\/fonc.2021.703143","volume":"11","author":"W Zhao","year":"2021","unstructured":"Zhao W, Jiang W, Wang H, He J, Su C, Yu Q. Impact of smoking history on response to immunotherapy in non-small-cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:703143.","journal-title":"Front Oncol"},{"issue":"19","key":"15738_CR21","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.1002\/cam4.4197","volume":"10","author":"LY Sun","year":"2021","unstructured":"Sun LY, Cen WJ, Tang WT, Long YK, Yang XH, Ji XM, et al. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer. Cancer Med. 2021;10(19):6610\u20137.","journal-title":"Cancer Med"},{"issue":"13","key":"15738_CR22","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3390\/cancers17132190","volume":"17","author":"F Markovi\u0107","year":"2025","unstructured":"Markovi\u0107 F, Hochmair M, M\u00fcser N, Fabikan H, Rodriguez VM, Janzic U, et al. The efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC aged \u226570 years with high PD-L1 (TPS \u2265 50%) expression: a multicenter real-world study. Cancers. 2025;17(13):2190.","journal-title":"Cancers"},{"issue":"7528","key":"15738_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"3","key":"15738_CR24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.4143\/crt.2021.764","volume":"54","author":"Q Yin","year":"2022","unstructured":"Yin Q, Dai L, Sun R, Ke P, Liu L, Jiang B. Clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with liver metastases: a network meta-analysis of nine randomized controlled trials. Cancer Res Treat. 2022;54(3):803\u201316.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"15738_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41416-023-02482-w","volume":"130","author":"FJ Qu","year":"2024","unstructured":"Qu FJ, Zhou Y, Wu S. Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. Br J Cancer. 2024;130(2):165\u201375.","journal-title":"Br J Cancer"},{"issue":"2","key":"15738_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","volume":"42","author":"D Memon","year":"2024","unstructured":"Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, et al. Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer. Cancer Cell. 2024;42(2):209-224 e209.","journal-title":"Cancer Cell"},{"issue":"12","key":"15738_CR27","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2217\/imt-2020-0262","volume":"13","author":"G Xiao","year":"2021","unstructured":"Xiao G, Liu Z, Gao X, Wang H, Peng H, Li J, et al. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Immunotherapy. 2021;13(12):1031\u201351.","journal-title":"Immunotherapy"},{"issue":"15","key":"15738_CR28","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1097\/CM9.0000000000002127","volume":"135","author":"W Liu","year":"2022","unstructured":"Liu W, Powell CA, Wang Q. Tumor microenvironment in lung cancer-derived brain metastasis. Chin Med J. 2022;135(15):1781\u201391.","journal-title":"Chin Med J"},{"issue":"5","key":"15738_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655\u201363.","journal-title":"Lancet Oncol"},{"key":"15738_CR30","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022;13:844866.","journal-title":"Front Immunol"},{"issue":"17","key":"15738_CR31","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","volume":"24","author":"K Woroniecka","year":"2018","unstructured":"Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2018;24(17):4175\u201386.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"15738_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15738_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"6","key":"15738_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15738_CR35","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24(6):e327\u201337.","journal-title":"Oncologist"},{"issue":"3","key":"15738_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/1759-7714.14274","volume":"13","author":"Y Shi","year":"2022","unstructured":"Shi Y, Fang J, Zhou C, Liu A, Wang Y, Meng Q, et al. Immune checkpoint inhibitor-related adverse events in lung cancer: real-world incidence and management practices of 1905 patients in China. Thorac Cancer. 2022;13(3):412\u201322.","journal-title":"Thorac Cancer"},{"issue":"2","key":"15738_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"15738_CR38","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"6280","key":"15738_CR39","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"key":"15738_CR40","first-page":"PO.20.00321","volume":"5","author":"JC Thompson","year":"2021","unstructured":"Thompson JC, Carpenter EL, Silva BA, Rosenstein J, Chien AL, Quinn K, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol. 2021;5:PO.20.00321.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"15738_CR41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018;174(3):549-563.e519.","journal-title":"Cell"},{"issue":"8","key":"15738_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan JP, Rey C, Bougouin A, Cousin S, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer. 2021;2(8):794\u2013802.","journal-title":"Nat Cancer"},{"issue":"7","key":"15738_CR43","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"6371","key":"15738_CR44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (New York, NY). 2018;359(6371):91\u20137.","journal-title":"Science (New York, NY)"},{"issue":"9","key":"15738_CR45","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"15738_CR46","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"8","key":"15738_CR47","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321\u20138.","journal-title":"Ann Oncol"},{"key":"15738_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejca.2018.05.015","volume":"100","author":"F Grossi","year":"2018","unstructured":"Grossi F, Crin\u00f2 L, Logroscino A, Canova S, Delmonte A, Melotti B, et al. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. European journal of cancer (Oxford, England\u202f: 1990). 2018;100:126\u201334.","journal-title":"European journal of cancer (Oxford, England : 1990)"},{"issue":"9","key":"15738_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","volume":"8","author":"G Middleton","year":"2020","unstructured":"Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8(9):895\u2013904.","journal-title":"Lancet Respir Med"},{"key":"15738_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Qui\u00f1ones-Hinojosa A, Zaorsky NG, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104\u201312.","journal-title":"Radiother Oncol"},{"issue":"11","key":"15738_CR51","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","volume":"16","author":"SF Powell","year":"2021","unstructured":"Powell SF, Rodr\u00edguez-Abreu D, Langer CJ, Tafreshi A, Paz-Ares L, Kopp HG, et al. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol. 2021;16(11):1883\u201392.","journal-title":"J Thorac Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15738-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:02:37Z","timestamp":1774522957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15738"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15738-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (PJ-YX2019-004) and was conducted in accordance with the Declaration of Helsinki and relevant local regulations. Given the retrospective design and the exclusive use of anonymized data, the Ethics Committee waived the requirement for written informed consent from individual participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data analyzed in this study were fully anonymized and de-identified. No identifying images or personal clinical details are included in the manuscript. Therefore, the Ethics Committee waived the requirement for obtaining consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}